Jane Street Group LLC Acquires 62,003 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Jane Street Group LLC boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 57.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,575 shares of the company’s stock after purchasing an additional 62,003 shares during the period. Jane Street Group LLC owned about 0.08% of Taysha Gene Therapies worth $293,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of TSHA. Cibc World Markets Corp acquired a new position in Taysha Gene Therapies during the 4th quarter worth approximately $28,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies during the 4th quarter worth approximately $31,000. Hsbc Holdings PLC grew its holdings in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after acquiring an additional 8,076 shares during the last quarter. AXQ Capital LP bought a new stake in Taysha Gene Therapies during the 4th quarter worth approximately $39,000. Finally, Virtus ETF Advisers LLC grew its holdings in Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock worth $55,000 after acquiring an additional 9,494 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TSHA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective (up from $6.00) on shares of Taysha Gene Therapies in a research note on Monday. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. JMP Securities boosted their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a “market outperform” rating in a research report on Thursday, May 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Finally, Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus target price of $7.57.

Taysha Gene Therapies Stock Performance

TSHA opened at $2.78 on Wednesday. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The company’s fifty day moving average price is $1.96 and its two-hundred day moving average price is $1.91. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $4.32. The company has a market cap of $596.76 million, a price-to-earnings ratio of 4.41 and a beta of 0.90.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same quarter in the prior year, the company posted ($0.10) earnings per share. On average, analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Paul B. Manning bought 750,000 shares of the stock in a transaction dated Friday, May 30th. The stock was bought at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the acquisition, the insider now directly owns 2,841,704 shares in the company, valued at approximately $7,814,686. This trade represents a 35.86% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.